Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADE + melphalan + prednisone versus melphalan + prednisone in previously untreated multiple myeloma
2004-001989-41Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing VELCADE + melphalan + prednisone with melphalan + prednisone (2 arms). Primary endpoint: Time to progression. Started Oct 2004; status: completed.
02
Drugs
bortezomibmelphalanprednisone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2004-001989-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001989-41.